An exclusive delegation coming from Australia – where leading drug development experts will converge.
The Agilex team would like to invite you to join us for an exclusive delegation, where leading drug development experts will converge to unveil unparalleled opportunities for UK-based biotech innovators by revealing a turn-key solution for clinical trials in Australia. Discover how Australia offers the world’s fastest regulatory approval pathway into the clinic – guaranteeing swift access to critical Proof of Concept data. Couple this by gaining insights into the most generous R&D tax rebate system where eligible Biotechs can receive 43.5% cash back on R&D spend, empowering your investment dollars to stretch further.
Agilex and our colleagues joining us on this roadshow will show you how you can accelerate your drug development journey with confidence, backed by Australia’s commitment to efficiency and excellence in Phase 1 clinical trials.
Unparalleled opportunity for UK biotechs to spend less and expedite clinical development by bringing their trials to Australia.
From September 23rd to 27th, a distinguished consortium of Australia’s leading biotech and clinical research organizations is embarking on a pivotal journey to the UK. Agilex Biolabs, Southern Star Research, Nucleus Network, IDT Australia, RDI Partners, and Scendea will unite forces to showcase Australia’s unrivalled capabilities in clinical trials and pharmaceutical development. Don’t miss this chance to ignite innovation and register now to unlock Australia’s potential for your next breakthrough. Find out more and RSVP here: www.gday-uk.com
Challenges in the UK clinical trials sector:
In 2023, an independent review of commercial clinical trials in the UK by Lord O’Shaughnessy was published which outlined 8 key problem statements as per the below (A link to the review can be found here – https://www.gov.uk/government/publications/commercial-clinical-trials-in-the-uk-the-lord-oshaughnessy-review/commercial-clinical-trials-in-the-uk-the-lord-oshaughnessy-review-final-report):
Problem statement 1: clinical trial set up and approval processes in the UK are slow and bureaucratic, especially compared to other countries
Problem statement 2: lack of transparency and data about commercial clinical trials activity in the UK
Problem statement 3: lack of accountability at every level for underperformance in clinical trials
Problem statement 4: research is not systematically prioritised by or within the NHS
Problem statement 5: doctors, nurses and NHS organisations lack incentives to take part in research, especially when it is commercially-funded
Problem statement 6: conversations about research are absent from many interactions between clinicians and patients. The topic has a low profile with the public, especially among disadvantaged or marginalised groups
Problem statement 7: we are failing to take advantage of the NHS’s considerable data assets
Problem statement 8: primary care is a negligible provider of clinical trial activity, despite the opportunities it provides for delivering population-scale trials, and there is too much reliance on hospital settings for the delivery of trials.
The Australian Solution:
Australia has become a haven for Phase 1 clinical trials in the last few years, clearly demonstrated by the fact that 70% of all FDA submissions since 2019 have some Australian data in them. Some of the reasons for this are:
- Cost Efficiency: Up to 20-30% cost savings due to favourable exchange rates and competitive pricing.
- Speed: Expedited regulatory pathways for swift initiation of clinical trials. No IND required to commence first-in-human trials, with approval possible within 4-6 weeks.
- Quality: Access to state-of-the-art facilities and top-tier scientific expertise and FDA inspected facilities.
- 43.5% Cash Back: Maximize investment through generous R&D tax rebates, allowing every dollar to stretch so much further
- Manufacturing: GMP material not required
Who’s Coming?
In partnership with the Australian Government, the following companies are joining forces to showcase an end-to-end solution:
- Agilex Biolabs: Australia’s largest and most technologically advanced biolab and toxicology provider with global reach.
- Southern Star Research: A premier Australian full-service CRO accelerating clinical programs worldwide.
- Nucleus Network: The only Phase 1 clinical trials specialist with units in Australia and the US.
- IDT Australia: Offering comprehensive contract manufacturing services.
- RDI Partners: Experts in R&D tax consulting, providing the gateway for innovation in Australia.
- Scendea: International leaders in product development and regulatory consulting for healthcare innovation.
What we’re Proposing:
Our consortium offers a turn-key solution for UK biotechs, pharma, and drug developers interested in conducting clinical trials in Australia. We bring together expertise in specialty lab services, clinical trial management, regulatory consulting, manufacturing and R&D tax incentives to streamline the path from Proof of Concept to market.
Purpose:
The purpose of this initiative is to educate and empower the biotech sector in the UK about the compelling advantages of choosing Australia for clinical development. Find out how you can take advantage of the cost savings, rapid regulatory approval timelines (as short as 4-5 weeks), and access to one of the most generous R&D tax rebate systems globally (up to 43.5% cash refund on R&D spend).
Events & Locations:
Events will be hosted in key UK biotech hubs including:
- Oxford Science Park – Oxford
- Victoria House – London
- TBC – London
- Babraham Research Campus – Cambridge
- Alderley Park – Maccelsfield
- TBC – Manchester
Participants will have the opportunity to engage with our experts through exclusive seminars and one-on-one networking discussions. We will look to step through what it looks like to conduct a clinical trial in Australia right from step 1 to ensure you know how to best access the incentives on offer.
Target Audience:
UK biotech companies, pharmaceutical firms, and drug developers seeking to accelerate their drug development pipeline, gain critical Proof of Concept data, and attract investor interest.
Join us now!
Don’t miss this opportunity to discover how Australia can propel your drug development efforts forward. Join us during our UK roadshow from September 23rd to 27th—reserve your limited spot today and unlock the potential of Australia for your next breakthrough!
